Marine-derived polygalactofucan and its β -2-deoxy-amino-substituted glucopyranan composite attenuate 3-hydroxy-3-methylglutaryl-CoA reductase: prospective natural anti-dyslipidemic leads
The objective of the work was to develop the marine-derived polysaccharides attenuating 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), and as prospective natural anti-dyslipidemic leads. Physical and chromatographic purification methods were used to isolate the polygalactofucan from the marine macroalgaSargassum wightii andβ-(2-deoxy)-amino-substituted glucopyrananan from a marine crustacean. Glycosidic linkage analysis by the process of methylation was used for structural elucidation of the polygalactofucan, and the methylated and partially methylated alditol acetates were characterized using extensive spectroscopic experiments. The polysaccharide composite constituting the titled polysaccharide motifs showed significant HMGCR inhibitory potential (IC90 0.12 mg mL−1) and an increase in HMG-CoA/mevalonate ratio (1.68 mg dL−1) compared with the high-fat diet (HFD)-treated animals (1.04 mg dL−1), which recognized its hypo-lipidemic efficacy. In vivo results demonstrated about 70% reduction in the triglyceride levels with the concomitant increase (~39%) of hepatic lipoprotein lipase (LPL) activity in the HFD-fed Wistar rats treated with 500 mg kg−1 body weight. The results illustrated the use of marine-derived polygalactofucan composite as potential anti-dyslipidemic agent.
CONCLUSIONS: The clinical polymorphism effectiveness outlined therein will be assured by diagnostic improvements suitable for driving treatment decisions. In light of our experimental results and literature data, the analysis of the SLCO1B1 T521C variant will allow clinicians to take advantage from a better treatment planned for their patients in order to minimize neuromuscular pain and maximize benefits. PMID: 31957862 [PubMed - in process]
No more effective than placebo; and their help with sleep problems might be short-lived as tolerance develops Related items fromOnMedica Statins of small and uncertain benefit in primary prevention Pharmacists could offer high-dose statins direct to patients UK research reveals racial inequalities in diabetes care Fund specialist dementia training to improve care and save money New evidence on benzodiazepine link to Alzheimer ’s
In this study, there was no increased risk of adverse outcomes (including muscle aches, liver dysfunction, new onset of diabetes, cancer, and bleeding strokes), even when LDL was lowered to as low as 20 mg/dL. Although statin medications themselves have been linked to side effects, especially at high doses, it appears that extremely low LDL concentrations are not responsible for side effects. In other words, lowering LDL beyond our previous target of 70 mg/dL appears to be not only safe but beneficial, in patients with CVD. The post LDL cholesterol: How low can you (safely) go? appeared first on Harvard Health Blog.
(Natural News) We’ve all had it drilled into our heads that high cholesterol is bad and bringing it down with statins can prevent a heart attack. However, that doesn’t explain why many people who take statins still end up developing cardiovascular disease. A recent study shows that there’s far more to the cardiovascular disease equation...
Study finds unequal dementia care Related items fromOnMedica Fund specialist dementia training to improve care and save money NHS care lets down 'far too many patients' Experts urge radical action on mental health crises CQC's State of Care report finds standards improving but warns of pressures Statins of small and uncertain benefit in primary prevention
CONCLUSION: HbA1c, hypertension, dyslipidemia and diabetic nephropathy are important risk factors for CVD in adults with type 1 diabetes. A longer follow-up is likely required to assess the impact of other traditional CVD risk factors on incident CVD in the current era. PMID: 31955209 [PubMed - as supplied by publisher]
DR MAX PEMBERTON: As a nation we've become enormously reliant on medication to manage our health and we happily reach for statins or blood pressure tablets.
ConclusionsMetformin can limit the development of atherosclerosis secondary to diabetes in young diabetic mice. A possible mechanism is the removal of methylglyoxal, thereby reducing the formation of advanced glycation endproducts, rather than by lowering the blood glucose level.FundingThis work was supported by the National Natural Science Foundation of China (81901106) and Jinan clinical medical science and technology innovation plan (201907002).
In this study, we reviewed in-vitro and in-vivo studies, as well as clinical reports pertaining to the antifungal efficacy of statins. In addition, we have addressed various modulators of statin anti-fungal activity and the potential mechanisms responsible for their anti-fungal effects. In general, statins do possess anti-fungal activity, targeting a broad spectrum of fungal organisms including human opportunistic pathogens such as Candida spp. and Zygomycetes, Dermatophytes, alimentary toxigenic species such as Aspergillus spp., and fungi found in device implants such as Saccharomyces cerevisiae. Statins have been shown t...